Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy

World Journal of Biological Psychiatry

Volumn 2, Issue 2, 2001, Pages 70-82

  Fukuzako, Hiroshi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

magnetic resonance spectroscopy; phosphorus metabolites; schizophrenia

Indexed keywords

CREATINE PHOSPHATE; NEUROLEPTIC AGENT; PHOSPHATASE; PHOSPHODIESTERASE; PHOSPHOLIPID;

BRAIN; DRUG EFFECT; FRONTAL LOBE; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; TEMPORAL LOBE;

ANTIPSYCHOTIC AGENTS; BRAIN; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOCREATINE; PHOSPHOLIPIDS; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORIC MONOESTER HYDROLASES; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 0035324318     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970109027496     Document Type: Article

References (128)

1. Adler LE, Freedman R, Ross RG, Olincy A, Waldo MC (1999) Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry 46:8-18.
2. 2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry 26:94-98.
3. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins CL, Ponto LLB, Hichwa RD (1997) Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349:1730-1734.
4. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer J-P, Rusinek H, Wolkin A, Cancro R, Schiffer W (1998) Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 155:337-343.
5. Berman I, Merson A, Sison C, Allan E, Schaefer C, Loberboym M, Losonczy MF (1996) Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: A pilot study. Psychopharmacology Bull 32:95-100.
6. 31P MRS of the schizophrenic brain in vivo. J Comp Assist Tomogr 23:272-275.
7. Bottomley PA (1989) Human in vivo NMR spectroscopy in diagnostic medicine: Clinical tool or research probe? Radiology 170:1-15.
8. Buchsbaum MS, Hazlett EA (1998) Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 24:343-364.
9. Byne W, Kemether E, Jones L, Haroutunian V, Davis KL (1999) The neurochemistry of schizophrenia. In: Charney DS, Nestler EJ, Bunney BS (eds) Neurobiology of Mental Illness. Oxford University Press, Oxford, pp 236-245.
10. Calabrese C, Deicken RF, Fein C, Merrin EL, Schoenfeld F, Weiner MW (1992) "Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biol Psychiatry 32:26-32.
11. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJP, Frank JA, Weinberger DR (1998) Hippocampal Nl-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biol Psychiatry 44:941-950.
12. Catafau AM, Parellada E, Lomeña FJ, Bernardo M, Pavía J, Ros D, Setoain J, Gonzalez-Monclús E (1994) Prefrontal and temporal blood flow in schizophrenia: Resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 35:935-941.
13. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, Durand C (1998) Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128:2512-2519.
14. Christensen JD, Holcomb I, Nair TR, Carver DL (1998) Schizophrenic prefrontal [PDE] correlates with residual symptoms following neuroleptic treatment (abstract). Proc 6th Ann Scientific Meeting SMR, p 503.
15. de-la-Presa-Owens S, Innis SM (1999) Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic and serotonergic neurotransmitters in frontal cortex caused by a linoleic and alphalinolenic acid deficient diet in formula-fed piglets. J Nutr 129:2088-2093.
16. Deicken RF, Calabrese G, Merrin EL, Meyerhoff DJ, Dillon WP, Weiner MW, Fein G (1994) "Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry 36:503-510.
17. Deicken RF, Calabrese G, Merrin EL, Fein G, Weiner MW (1995a) Basal ganglia phosphorous metabolism in chronic schizophrenia. Am J Psychiatry 152:126-129.
18. 31Phosphorus magnetic resonance spectroscopic imaging study. Biol Psychiatry 38:279-286.
19. Deicken RF, Merrin EL, Floyd TC, Weiner MW (1995c) Correlation between left frontal phospholipids and Wisconsin Card Sorting Test performance in schizophrenia. Schizophr Res 14:177-181.
20. Delion S, Chalon S, Herault I, Guilloteau D, Besnard JC, Durand G (1994) Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. J Nutr 124:2466-2475.
21. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G (1996) Alpha-linolenic acid deficiency alters age-related changes of dopaminergic and serotonergic neurotransmission in rats. J Neurochem 66:1582-1591.
22. DeLisi LE, Buchsbaum MS, Holcomb HH, Laugston KC, King AC, Kessler R, Pickar D, Carpenter WT, Morihisa JM, Margolin R, Weinberger DR (1989) Increased temporal lobe glucose use in chronic schizophrenic patients. Biol Psychiatry 25:835-851.
23. Demisch L, Gerbaldo H, Gebhart P, Georgi K, Bochnik HJ (1987) Incorporation of "C-arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disorders. Psychiatry Res 22:275-282.
24. 2 and schizophrenia. Schizophr Res 31:185-196.
25. Egan MF, Weinberger DR (1997) Neurobiology of schizophrenia. Curr Opin Neurobiol 7:701-707.
26. Ernst T, Kreis R, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. Part I: Compartments and water. J Magn Reson 102:1-8.
27. Farooqui AA, Hirashima Y, Horrocks LA (1992) Brain phospholipases and their role in signal transduction. In: Bazan NG, Murphy MG, Tofano G (eds) Neurobiology of Essential Fatty Acids. Plenum Press, New York, pp 11-26.
28. Fenton WS, Hibbeln J, Knable M (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47:8-21.
29. Frahm J, Michaelis T, Merboldt K-D, Hanicke W, Gyngell ML, Chien D, Bruhn H (1989) Localized NMR spectroscopy in vivo: Progress and Problems. NMR Biomed 2:188-195.
30. 51P chemical shift imaging (abstract). Proc Soc Magn Reson Med, p 1935
31. 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand 86:455-462.
32. Fukuzako H, Takeuchi K, Ueyama K, Fukuzako T, Hokazono Y, Hirakawa K, Yamada K, Hashiguchi T, Takigawa M, Fujimoto T (1994) 3, P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms. Eur Arch Psychiatry Clin Neurosci 244:236-240.
33. Fukuzako H, Fukuzako T, Takeuchi K, Ohbo Y, Ueyama K, Takigawa M, Fujimoto T (1996) Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Prog Neuropsychopharmacol Biol Psychiat 20:629-640.
34. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T (1999a) Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 156:1205-1208.
35. Fukuzako H, Fukuzako T, Kodama S, Hashiguchi T, Takigawa M, Fujimoto T (1999b) Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 21:542-549.
36. 2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol Psychiatry 22:421-426.
37. 2 activity in schizophrenia. Schizophr Res 16:1-6.
38. Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, Skinner FS (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res 12:53-61.
39. Gur RE, Gur RC, Skolnik BE, Caroff S, Obrist WO, Resnick S, Reirich S (1985) Brain function in psychiatric disorders: III. Regional cerebral blood flow in unmedicated schizophrenics. Arch Gen Psychiatry 42:329-334.
40. Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M, Cur RC (1995) Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52:657-667.
41. Harrison PJ (1999) The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain 122:593-624.
42. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133-139.
43. Hinsberger AD, Williamson PC, Carr TJ, Stanley JA, Drost DJ, Densmore M, MacFabe GC, Montemurro DG (1997) Magnetic resonance imaging volumetric and phosphorus 31 magnetic resonance spectroscopy measurements in schizophrenia. J Psychiatry Neurosci 22:111-117.
44. Horrobin DF (1998) The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30:193-208.
45. Horrobin DF, Bennett CN (1999) New gene targets related to schizophrenia and other psychiatric disorders: Enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 60:141-167.
46. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M (1991) Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30:795-805.
47. Horrobin DF, Glen AIM, Cantrill RC (1997) Clozapine: Elevation of membrane unsaturated lipid levels as a new mechanism of action (abstract). Schizophr Res 24:214.
48. 2 associated with schizophrenia. Schizophr Res 21:111-116.
49. Hugg JW, Matson GB, Twieg DB, Maudsley AA, Sappey-Marinier D, Weiner MW (1992) Phosphorous-31 MR spectroscopic imaging (MRSI) of normal and pathological brains. Magn Reson Imaging 10:227-243.
50. Hughes JR (1996) A review of the usefulness of the standard EEC in psychiatry. Clin Electroencephalogr 27:35-39.
51. 1H-coupled in normal human volunteers (abstract). Proc 7th Ann Scientific Meeting SMR, p 1419.
52. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghom JM (1993) Three clinical syndromes of schizophrenia in untreated subjects: Relation to brain glucose activity measured by positron emission tomography. Schizophr Res 11:47-54.
53. 2 activity between acute psychiatric patients and controls. Schizophr Res 26:103-105.
54. Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S (1995) Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res Neuroimag 61:151-160.
55. Kegeles LS, Humaran TI, Mann JJ (1998) In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry 44:382-398.
56. Keshavan MS, Pettegrew JW, Panchalingam K, Kaplan D, Bozik E (1991) Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. Arch Gen Psychiatry 48:1112-1113.
57. 31P MRS and MRI studies. Schizophr Res 10:241-246.
58. Keshavan MS, Pettegrew JW, Panchalingam K (1995a) MRS in the study of psychoses: psychopharmacological studies. In: Nasrallah HA, Pettegrew JW (eds) NMR Spectroscopy in Psychiatric Brain Disorders. American Psychiatric Press, Washington DC, pp 131-146.
59. Keshavan MS, Pettegrew JW, Reynolds CF, Panchalingam KS, Montrose D, Miewald J, Kupfer DL (1995b) Biological correlates of slow wave sleep deficits in functional psychoses: "P-magnetic resonance spectroscopy. Psychiatry Res 57:91-100.
60. Keshavan MS, Stanley JA, Pettegrew JW (2000) Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-Part II. Biol Psychiatry 48:369-380.
61. Kilby PM, Allis JL, Radda GK (1990) Spin-spin relaxation of the phosphodiester resonance in the 3, P NMR spectrum of human brain: the determination of the concentrations of phosphodiester components. FEBS Lett 272:163-165.
62. 31P-NMR study of brain phospholipid structures in vivo. Biochim Biophys Acta 1085:257-264.
63. Kjome JR, Swenson KA, Johnson MN, Bordayo EZ, Anderson LE, Klevan LC, Fraticelli Al, Aldrich SL, Fawcett JR, Venters HD Jr, Ala TA, Frey WH (1998) Inhibition of antagonist and agonist binding to the human muscarinic receptor by arachidonic acid. J Mol Neurosci 10:209-217.
64. Klemm E, Danos P, Grünwald F, Kasper S, Möller H-J, Biersack H-J (1996) Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression: A study with single photon emission computed tomography. Psychiatry Res Neuroimag 68:1-10.
65. Kunugi H, Hattori M, Nanko S, Fujii K, Kato T (1999) Dinucleotide repeat polymorphism in the neurotrophin-3 gene and hippocampal volume in psychoses. Schizophr Res 37:271-273.
66. 2 receptor gene. Mol Psychiatry 3:261-265.
67. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ (1992) Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-186.
68. 31P MRS of the normal adult human brain: Assessment of interindividual differences and aging effects. NMR Biomed 6:53-57.
69. Maier M (1995) In vivo magnetic resonance spectroscopy: applications in psychiatry. Br J Psychiatry 167:299-306.
70. McCarley RW, Shenton ME, O'Donnell BF, Nestor PG (1993) Uniting Kraepelin and Bleuler: The Psychology of schizophrenia and the biology of temporal lobe abnormalities. Harv Rev Psychiatry 1:36-56.
71. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, Shenton ME (1999) MRI anatomy of schizophrenia. Biol Psychiatry 45:1099-1119.
72. McClure RJ, Keshavan MS, Pettegrew JW (1998) Chemical and physiologic brain imaging in schizophrenia. Psychiat Clin North America 21:93-122.
73. 31P NMR spectra of the human brain in vivo. NMR Biomed 7:237-242.
74. Mellor JE, Laugharne JDE, Peet M (1995) Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res 18:85-86.
75. Miller B, Sarantis M, Traynelis SF, Attwell D (1992) Potentiation of NMDA receptor currents by arachidonic acid. Nature 355:722-725.
76. Miller DD, Rezai K, Alliger R, Andreasen NC (1997) The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: Assessment with technetium-99m hexamethylpropyleneamine oxime single photon emission computed tomography. Biol Psychiatry 41:550-559.
77. Muller N, Riedel M, Ackenheil M, Schwarz MJ (1999) The role of immune function in schizophrenia: An overview. Eur Arch Psychiatry Clin Neurosci 249:62S-68S.
78. 31P NMR spectrum in vivo. Magn Reson Med 12:282-289.
79. Nilsson A, Risberg J, Johnason M, Gustafson L (1977) Regional changes of cerebral blood flow during haloperidol therapy in patients with paranoid symptoms. Acta Neurol Scand Suppl 64:478-479.
80. 2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 34:641-649.
81. Nordahl TE, Kusubov N, Carter C, Salamat S, Cummings AM, O'Shora-Celaya L, Eberling J, Robertson L, Huesman RH, Jagust W, Budinger TF (1996) Temporal lobe metabolic differences in medication-free outpatients with schizophrenia via the PET-600. Neuropsychopharmacology 15:541-554.
82. 31P magnetic resonance spectroscopy. Biol Psychiatry 29:1149-1152.
83. Peet M, Mellor J (1998) Double-blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Presented at the 9th Schizophrenia Winter Workshop. Davos, Switzerland.
84. Peet M, Ramchand CN, Lee J, Telang SD, Vankar GK, Shah S, Wei J (1998) Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia. Psychiatr Genet 8:191-192.
85. Pettegrew JW, Keshavan MS, Minshew NJ, McClure RI (1995) 31P-MRS of metabolic alterations in schizophrenia and neurodevelopment. In: Nasrallah HA, Pettegrew JW (eds) NMR Spectroscopy in Psychiatric Brain Disorders. American Psychiatric Press, Washington DC, pp 45-77.
86. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, Allen M (1991) Alterations in brain highenergy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics: A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48:563-568.
87. Potwarka J, Drost DJ, Williamson PC, Carr T, Canaran G, Rylett WJ, Neufeld RWJ (1999) A 'H-decoupled 3, P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry 45:687-693.
88. Price SA, Fox H, St Clair D, Shaw DJ (1997) Lack of association between schizophrenia and polymorphism close to the cytosolic phospholipase A2 gene. Psychiatr Genet 7:111-114.
89. Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, Hajnal JV, Bydder GM (2000) Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalization of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 54:57-63.
90. 31P-MRS reveals gender differences in healthy controls, not in schizophrenics. NMR Biomed 12:483-489.
91. 2. Arch Gen Psychiatry 54:487-494.
92. 2 activities in brain of patients with schizophrenia. Brain Res 821:407-413.
93. Russell JM, Early TS, Patterson JC, Martin JL, Villanneva-Meyer J, McGee MD (1997) Temporal lobe perfusion asymmetries in schizophrenia. J Nucl Med 38:607-612.
94. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U (1997) Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 349:1735-1739.
95. 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab 12:584-592.
96. Shihabuddin L, Silverman JM, Buchsbaum MS, Siever LJ, Luu C, Germans MK, Metzger M, Mohs RC, Smith CJ, Spiegel-Cohen J, Davis KL (1997) Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigree. Mol Psychiatry 1:215-222.
97. Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S (1994) Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res Neuroimag 55:223-235.
98. Shioiri T, Someya T, Murashita J, Kato T, Hamakawa H, Fujii K, Inubushi T (1997) Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res Neuroimag 76:113-122.
99. Singh SP, Shankar R (1996) Effect of haloperidol on phospholipid biosynthesis in rat brain. Ind J Exp Biol 34:111-114.
100. 31P MRS study of clozapine vs haloperidol effects on brain metabolism (abstract). Biol Psychiatry 37:648.
101. Smith CD, Pettigrew LC, Avison MJ, Kirsch JE, Tinkhtman AJ, Schmitt FA, Wermeling DP, Wekstein DR, Markesberry WR (1995) Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol 38:194-201.
102. 31P-MR spectroscopy study. Schizophr Res 1 3:209-215.
103. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, Thompson RT (1995) An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 52:399-406.
104. Stanley JA, Panchalingam K, Miller G, McClure RJ, Pettegrew JW (1997) A new method to quantify the broad component under the phosphodiester resonance and its application to study first-episode never medicated schizophrenics (abstract). Proc 5th Ann Scientific Meeting SMR, p 1408.
105. 31P MRS study (abstract). Biol Psychiatry 45:57S.
106. Stanley JA, Pettegrew JW, Keshavan MS (2000) Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-Part I. Biol Psychiatry 48:357-368.
107. Takeuchi K, Takigawa M, Fukuzako H, Hokazono Y, Hirakawa K, Fukuzako T, Ueyama K, Fujimoto T, Matsumoto K (1994) Correlation of third ventricular enlargement and EEG slow wave activity in schizophrenic patients. Psychiatry Res Neuroimag 55:1-11.
108. 2 activity in the brain of rats. Eur Arch Psychiatry Clin Neurosci 245:179-182.
109. Twieg DB, Meyerhoff DJ, Hubesch B, Roth K, Sappey-Marinier D, Boska MD, Gober JR, Schaefer S, Weiner MW (1989) Phosphorus-31 magnetic resonance spectroscopy in humans by spectroscopic imaging: Localized spectroscopy and metabolite imaging. Magn Reson Med 12:291-305.
110. Vance ALA, Velakoulis D, Maruff P, Wood SJ, Desmond P, Pantelis C (2000) Magnetic resonance spectroscopy and schizophrenia: What have we learnt?. Aust NZ J Psychiatry 34:14-25.
111. 2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem 64:2765-2772.
112. 31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique: Preliminary findings. Biol Psychiatry 41:644-648.
113. 31P-magneto- resonance spectroscopic study. Psychiatry Res Neuroimag 76:123-129.
114. 31phosphorus magnetic resonance spectroscopic and neuropsychological investigation. Schizophr Res 31:37-47.
115. Volz H-P, Rzanny R, Rößger G, Hübner G, Kreischmann-Andermahr I, Kaiser WA, Sauer H (1998b) "Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics: A study including 50 patients and 36 controls. Biol Psychiatry 44:399-404.
116. Volz H-P, Rößger G, Riehemann S, Hübner G, Maurer I, Wenda B, Rzanny R, Kaiser WA, Sauer H (1999) Increase of phosphodiesters during neuroleptic treatment of schizophrenics: A longitudinal 3'P-magnetic resonance spectroscopic study. Biol Psychiatry 45:1221-1225.
117. 31P chemical shift spectroscopic-imaging study. Biol Psychiatry 47:954-961.
118. Walker NP, Fox HC, Whalley LJ (1999) Lipids and schizophrenia. Br J Psychiatry 174:101-104.
119. Wassink TH, Nelson JJ, Crowe RR, Andreasen NC (1999) Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 88:724-728.
120. 2 gene associated with schizophrenia? Mol Psychiatry 3:480-481.
121. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 55:115-118.
122. 31P-MRS in the study of schizophrenia. In: Nasrallah HA, Pettegrew JW (eds) NMR Spectroscopy in Psychiatric Brain Disorders. American Psychiatric Press, Washington DC, pp 107-129.
123. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H (1991) Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 48:578.
124. Williamson P, Pelz D, Merskey H, Morrison S, Karlik S, Drost D, Carr T, Conlon P (1992) Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am J Psychiatry 149:549-551.
125. Witt M-R, Nielsen M (1994) Characterization of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro. I Neurochem 62:1432-1439.
126. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET (2000) Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157:16-25.
127. Yao JK, Yasaei P, van Kammen DP (1992) Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 46:39-46.
128. Yao JK, Leonard S, Reddy RD (2000) Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42:7-17.